Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9924788 | 0.97 | RAB9A (0.36) | RAB9ASPHK1SCN9ASPHK2FFAR4 | |
| SCHEMBL9924918 | 0.93 | SCN9A (0.34) | SPHK1SCN9AFFAR4 | |
| SCHEMBL9924989 | 0.92 | RAB9A (0.36) | RAB9ASPHK1SCN9ASPHK2FFAR4 | |
| SCHEMBL9924900 | 0.92 | SPHK1 (0.38) | RAB9ASPHK1SCN9ASPHK2 | |
| SCHEMBL9924919 | 0.90 | SPHK1 (0.41) | RAB9ASPHK1SCN9ASPHK2FFAR4 | |
| SCHEMBL9924925 | 0.90 | SCN9A (0.33) | SPHK1SCN9AFFAR4 | |
| SCHEMBL9924782 | 0.90 | SCN9A (0.35) | SPHK1SCN9ASPHK2FFAR4 | |
| SCHEMBL9924962 | 0.89 | SCN9A (0.35) | SPHK1SCN9AFFAR4 | |
| SCHEMBL9924924 | 0.88 | RAB9A (0.43) | RAB9ASCN9A | |
| SCHEMBL9924791 | 0.87 | SCN9A (0.34) | SPHK1SCN9AFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468707-B1 | DECAHYDRONAPHTHALENE COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS CONTAINING THE COMPOUNDS, AND LIQUID CRYSTAL DISPLAY DEVICES CONTAINING THE LIQUID CRYSTAL COMPOSITIONS | JNC CORP (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-8465674-B2 | Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition | JNC CORPORATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-8465674-B2 | Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition | JNC CORPORATION (JP) | 2013-06-18 | — | — | US | disclosed |
| EP-2468707-A1 | DECAHYDRONAPHTHALENE COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS CONTAINING THE COMPOUNDS, AND LIQUID CRYSTAL DISPLAY ELEMENTS CONTAINING THE LIQUID CRYSTAL COMPOSITIONS | JNC Corporation (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120145959-A1 | DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120145959-A1 | DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145959-A1 | DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION | DCUN1D2, OCIAD1, CPNE4 | RAB9A 4571/4885SPHK1 2935/4885SCN9A 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.